Protocol 1: the gentle start (for GI-sensitive individuals) Goal: Minimize side effects completely while building to a therapeutic dose Best for: People with histories of medication sensitivity, IBS, acid reflux, or those who tried standard tirzepatide and could not tolerate it Complete schedule: Weeks 1-2: 0.125 mg weekly Weeks 3-4: 0.25 mg weekly Weeks 5-6: 0.5 mg weekly Weeks 7-8: 0.75 mg weekly Weeks 9-10: 1.0 mg weekly Weeks 11-14: 1.5 mg weekly Weeks 15-18: 2.0 mg weekly Weeks 19-22: 2.5 mg weekly Weeks 23-26: 5.0 mg weekly Time to therapeutic dose: 22-26 weeks Expected results: Minimal GI discomfort, gradual appetite reduction beginning around weeks 7-10, meaningful weight loss starting around weeks 15-18 This protocol takes nearly six months to reach 5 mg, but for someone who previously abandoned treatment due to side effects, six months on treatment beats three weeks of misery followed by quitting
Type 1 diabetes as although primarily studied in type 2 diabetes, there is potential for adjunctive use in type 1 diabetes management
Conclusion The exploration of GLP-1 and GLP-2 pathways has provided an emerging hypothesis and therapeutic rationale for intestinal repair in IBD
Editorial refresh Practical 2026 note for Sermorelin vs GHK This update makes Sermorelin vs GHK more specific by tying BPC-157, sermorelin, ghk, which, better to the page's original clinical, cost, access, or comparison angle
Patients who have struggled with traditional diet and exercise alone, or who regain weight quickly after previous loss, often show strong candidacy even if their current BMI is borderline
